Becton Dickinson Net Profit Margin 2010-2023 | BDX

Current and historical net profit margin for Becton Dickinson (BDX) from 2010 to 2023. Net profit margin can be defined as net Income as a portion of total sales revenue. Becton Dickinson net profit margin for the three months ending December 31, 2023 was .
Becton Dickinson Net Profit Margin Historical Data
Date TTM Revenue TTM Net Income Net Margin
2023-12-31 $19.49B $1.22B 6.25%
2023-09-30 $19.37B $1.42B 7.35%
2023-06-30 $19.05B $1.58B 8.30%
2023-03-31 $18.81B $1.53B 8.12%
2022-12-31 $18.74B $1.52B 8.11%
2022-09-30 $18.87B $1.69B 8.95%
2022-06-30 $18.41B $1.67B 9.05%
2022-03-31 $18.38B $1.83B 9.96%
2021-12-31 $18.53B $1.68B 9.04%
2021-09-30 $19.13B $2.00B 10.46%
2021-06-30 $18.57B $1.87B 10.04%
2021-03-31 $17.82B $1.64B 9.20%
2020-12-31 $17.16B $1.51B 8.79%
2020-09-30 $16.07B $0.77B 4.77%
2020-06-30 $16.92B $0.79B 4.65%
2020-03-31 $17.41B $0.92B 5.30%
2019-12-31 $17.36B $0.76B 4.38%
2019-09-30 $17.29B $1.08B 6.26%
2019-06-30 $17.11B $0.78B 4.58%
2019-03-31 $17.04B $0.93B 5.44%
2018-12-31 $17.06B $0.90B 5.25%
2018-09-30 $15.98B $0.16B 0.99%
2018-06-30 $14.75B $0.62B 4.21%
2018-03-31 $13.50B $-0.10B -0.74%
2017-12-31 $12.25B $0.29B 2.40%
2017-09-30 $12.09B $1.03B 8.52%
2017-06-30 $12.16B $0.76B 6.25%
2017-03-31 $12.32B $1.32B 10.67%
2016-12-31 $12.42B $1.31B 10.54%
2016-09-30 $12.48B $0.98B 7.82%
2016-06-30 $12.31B $1.14B 9.24%
2016-03-31 $12.23B $0.81B 6.62%
2015-12-31 $11.22B $0.69B 6.13%
2015-09-30 $10.28B $0.70B 6.76%
2015-06-30 $9.42B $0.82B 8.65%
2015-03-31 $8.46B $1.08B 12.75%
2014-12-31 $8.48B $1.15B 13.56%
2014-09-30 $8.45B $1.19B 14.03%
2014-06-30 $8.35B $0.97B 11.67%
2014-03-31 $8.24B $0.95B 11.53%
2013-12-31 $8.17B $0.94B 11.49%
2013-09-30 $8.05B $1.29B 16.05%
2013-06-30 $7.92B $1.49B 18.84%
2013-03-31 $7.85B $1.52B 19.33%
2012-12-31 $7.78B $1.53B 19.70%
2012-09-30 $7.71B $1.17B 15.18%
2012-06-30 $7.61B $1.18B 15.52%
2012-03-31 $7.58B $1.20B 15.79%
2011-12-31 $7.57B $1.22B 16.08%
2011-09-30 $7.58B $1.27B 16.76%
2011-06-30 $7.34B $1.37B 18.64%
2011-03-31 $7.22B $1.33B 18.45%
2010-12-31 $7.10B $1.32B 18.57%
2010-09-30 $7.12B $1.32B 18.50%
2010-06-30 $7.22B $1.24B 17.14%
2010-03-31 $7.21B $1.27B 17.64%
2009-12-31 $7.14B $1.24B 17.30%
Sector Industry Market Cap Revenue
Medical Medical & Dental Supplies $67.638B $19.372B
Becton, Dickinson and Company, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. BD's operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. The company's organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional. BD Medical: BD Medical's major product lines include needles, syringes and intravenous catheters for medication delivery and generic prefilled injectables. BD Life Sciences - BD Diagnostics provides products for the safe collection and transport of diagnostics specimens to detect a broad range of infectious diseases, healthcare-associated infections and cancer. BD Biosciences produces research and clinical tools that facilitate the study of cells to gain a better understanding of normal and disease processes. With the acquisition of C.R. Bard, BD added a new segment - BD Interventional.
Stock Name Country Market Cap PE Ratio
McKesson (MCK) United States $68.967B 18.46
West Pharmaceutical Services (WST) United States $27.235B 46.04
Cardinal Health (CAH) United States $26.315B 15.82
Align Technology (ALGN) United States $22.499B 45.37
Cooper (COO) United States $17.972B 27.19
Labcorp (LH) United States $16.950B 14.47
Henry Schein (HSIC) United States $9.104B 15.75
DENTSPLY SIRONA (XRAY) United States $6.325B 16.67
Merit Medical Systems (MMSI) United States $4.182B 23.93
Patterson (PDCO) United States $2.331B 11.17
STAAR Surgical (STAA) United States $2.267B 71.37
CONMED (CNMD) United States $2.237B 21.06
Atrion (ATRI) United States $0.708B 36.48
Lifevantage (LFVN) United States $0.086B 13.96
Pro-Dex (PDEX) United States $0.067B 25.33
Biolase (BIOL) United States $0.005B 0.00